HD-PLC-ALLIANCE
16.3.2021 07:02:09 CET | Business Wire | Press release
In order to integrate the latest improvements in speed and range of the HD-PLC*1 technology promoted by HD-PLC Alliance*2 , the Alliance has proposed the specifications of the next generation technology to the IEEE Standards Association*3 . To the great satisfaction of the Alliance members, recently published IEEE 1901-2020 Standard includes the latest HD-PLC features that provide higher speed, longer range wired communications over existing metal wires (control cable, coaxial cable, power cable, etc.).
Compared with wireless communication systems, HD-PLC enables more secure, stable and reliable communications. Furthermore, the use of existing cables allows a network infrastructure to cover not only indoors such as homes, buildings and factories but also outdoors extending several kilometers.
Mr. Yoshiyuki Miyabe, Senior Adviser of HD-PLC Alliance and Senior Managing Executive Officer of Panasonic Corporation, has sent a message, “Our company and HD-PLC Alliance have developed the HD-PLC technology cooperatively, which is now published as IEEE 1901-2020 standard. We anticipate this standardization will help make HD-PLC a breakthrough technology for the coming era of IoT. Making the most of this result for various products and business solutions for the future, we endeavor to further support innovation and advancement of the technology to provide new values to our customers.”
HD-PLC Alliance devotes its efforts to promote the technology through a certification program and logo. The test environment is being updated to offer the current third-generation communication compatibility services as well as upcoming fourth generation interoperability certification services compliant with IEEE 1901-2020.
On March 18, 2021, a webinar*4 on this technology will be held, organized by IEEE SA and HD-PLC Alliance. Also, please visit our renewed website.*5
Related Information:
HD-PLC Alliance members Press Release
[Panasonic Corporation]
Licensing IP Core for Semiconductors Complying with the IEEE 1901–2020 International Standard
https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html
[Socionext Inc.]
Socionext Agrees With MIRAIT, MMD, And Nuri Telecom On Next-Generation Long-Distance Power Line Communications For Verification And Social Implementation
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf
(Note) |
|
*1: |
HD-PLC™: A registered trademark or trademark of Panasonic Corporation in Japan and other countries. |
*2: |
HD-PLC Alliance: Established on September 25, 2007 with the aim to expand the use of High-definition Power Line Communication (HD-PLC) and to ensure communication compatibility. |
*3: |
IEEE Standards Association: Standards association within the Institute of Electrical and Electronics Engineers (IEEE) |
IEEE 1901-2020 standard: https://standards.ieee.org/standard/1901-2020.html |
|
*4: |
IEEE SA and HD-PLC Alliance Webinar March 2021 |
|
Subtitle: Home networking, Industrial and Building automation through HD-PLC (High-Speed Powerline Communication) |
Learn more: https://standards.ieee.org/events/index.html |
|
*5: |
HD-PLC Alliance Homepage: https://hd-plc.org/ |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005273/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom